NSE filing, NSE: ROSSARI. Summary written from the filing by ALFA Finder's alert engine.
Rossari Biotech Ltd: key numbers
- Share price
- ₹408.40
- Market cap
- ₹2,262 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 14.8×Sector 34.1×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.